Background/Aim: To evaluate the outcome and toxicities in patients with locally advanced cervical cancer (LACC) treated with radiochemotherapy and intracavitary brachytherapy. Patients and Methods: This study included 67 patients with LACC treated between 2010 and 2018. The most represented stage was FIGO IIB. The patients were treated with external beam radiotherapy (EBRT) to the pelvis and boost to the cervix and parametrials. Concomitant chemotherapy (CHT) with cisplatin (CDDP) 40 mg/mq was planned. Subsequently, the patients underwent CT-based endouterine brachytherapy (BT). The response was evaluated at 3 months with PET-CT and/or pelvic magnetic resonance imaging (MRI). Since then, the patients have been followed with clinical instrumental controls every 4 months for the first 2 years and every 6 months for the following 3 years. Local response was assessed with pelvic MRI and/or PET-CT scan at the end of intracavitary BT) according to RECIST 1.1 criteria. Results: The median duration of treatment was 55 days (range=40-73 days). The prescription dose to the planning target volume (PTV) was delivered in 25 to 30 (median 28) daily fractions. The EBRT median dose to the pelvis and gross tumor volume were 50.4 Gy (range=45-56.25) and 61.6 Gy (range=45-70.4), respectively. The 1-year, 2-year, 3-year, and 5-year overall survival rates were 92.44%, 80.81%, 78.84%, and 76.45% respectively. The actuarial 1-year, 2-year, 3-year, and 5-year disease-free survival rates were 89.5%, 83.6%, 81%, and 78.2% respectively. Conclusion: This study analyzed acute and chronic toxicity, survival, and local control in cervical cancer patients treated with IMRT followed by CT-planned high dose rate-brachytherapy. Patients demonstrated satisfactory outcomes and incidence of acute and late toxicities.

Clinical Outcomes and Toxicity of CT-guided High Dose-rate Brachytherapy in Women With Locally-advanced Cervical Cancer / DE SANCTIS, Vitaliana; GIUSEPPE FACONDO, 1; GIANLUCA VULLO, 1; DIMITRI ANZELLINI, 1; GIUSEPPE SANGUINETI, 1; ALESSIA NARDANGELI, 2; LUCA MARMIROLI, 2; FRANCESCA TORTORETO, 3; PIERCARLO GENTILE, 3; IVAN ANNESSI, 4; VITTORIO DONATO, 4; CINZIA CHIOSTRINI, 5; VINCENZO TOMBOLINI, 5; DE FELICE, Francesca; MAURIZIO VALERIANI, 6; and MATTIA FALCHETTO OSTI1, 1. - In: CANCER DIAGNOSIS & PROGNOSIS. - ISSN 2732-7787. - 3:2(2023), pp. 194-200. [10.21873/cdp.10201]

Clinical Outcomes and Toxicity of CT-guided High Dose-rate Brachytherapy in Women With Locally-advanced Cervical Cancer

VITALIANA DE SANCTIS;6 FRANCESCA DE FELICE;
2023

Abstract

Background/Aim: To evaluate the outcome and toxicities in patients with locally advanced cervical cancer (LACC) treated with radiochemotherapy and intracavitary brachytherapy. Patients and Methods: This study included 67 patients with LACC treated between 2010 and 2018. The most represented stage was FIGO IIB. The patients were treated with external beam radiotherapy (EBRT) to the pelvis and boost to the cervix and parametrials. Concomitant chemotherapy (CHT) with cisplatin (CDDP) 40 mg/mq was planned. Subsequently, the patients underwent CT-based endouterine brachytherapy (BT). The response was evaluated at 3 months with PET-CT and/or pelvic magnetic resonance imaging (MRI). Since then, the patients have been followed with clinical instrumental controls every 4 months for the first 2 years and every 6 months for the following 3 years. Local response was assessed with pelvic MRI and/or PET-CT scan at the end of intracavitary BT) according to RECIST 1.1 criteria. Results: The median duration of treatment was 55 days (range=40-73 days). The prescription dose to the planning target volume (PTV) was delivered in 25 to 30 (median 28) daily fractions. The EBRT median dose to the pelvis and gross tumor volume were 50.4 Gy (range=45-56.25) and 61.6 Gy (range=45-70.4), respectively. The 1-year, 2-year, 3-year, and 5-year overall survival rates were 92.44%, 80.81%, 78.84%, and 76.45% respectively. The actuarial 1-year, 2-year, 3-year, and 5-year disease-free survival rates were 89.5%, 83.6%, 81%, and 78.2% respectively. Conclusion: This study analyzed acute and chronic toxicity, survival, and local control in cervical cancer patients treated with IMRT followed by CT-planned high dose rate-brachytherapy. Patients demonstrated satisfactory outcomes and incidence of acute and late toxicities.
2023
cervix; radiotherapy; brachytherapy; lacc; hdr-bt
01 Pubblicazione su rivista::01a Articolo in rivista
Clinical Outcomes and Toxicity of CT-guided High Dose-rate Brachytherapy in Women With Locally-advanced Cervical Cancer / DE SANCTIS, Vitaliana; GIUSEPPE FACONDO, 1; GIANLUCA VULLO, 1; DIMITRI ANZELLINI, 1; GIUSEPPE SANGUINETI, 1; ALESSIA NARDANGELI, 2; LUCA MARMIROLI, 2; FRANCESCA TORTORETO, 3; PIERCARLO GENTILE, 3; IVAN ANNESSI, 4; VITTORIO DONATO, 4; CINZIA CHIOSTRINI, 5; VINCENZO TOMBOLINI, 5; DE FELICE, Francesca; MAURIZIO VALERIANI, 6; and MATTIA FALCHETTO OSTI1, 1. - In: CANCER DIAGNOSIS & PROGNOSIS. - ISSN 2732-7787. - 3:2(2023), pp. 194-200. [10.21873/cdp.10201]
File allegati a questo prodotto
File Dimensione Formato  
DeSanctis_Clinical-Outcomes-andToxicity-of CT-guided_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.54 MB
Formato Adobe PDF
1.54 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1675497
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 40
social impact